OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN)

#3220

Introduction: The perception of information provided to patients with cancer upon diagnosis may influence adherence to treatment and QoL, but data are scarce in GEP-NETs.

Aim(s): To evaluate the evolution of perception of information and QoL in patients with GEP-NET from initiation of lanreotide (LAN) to 6 months (M6).

Materials and methods: Patients with G1/G2 GEP-NET for whom the decision of LAN 120 mg/28 days initiation was taken independently from enrolment were included in this study. They completed EORTC QLQ-INFO25 and QLQ-C30 questionnaires before LAN initiation and at M6. Primary endpoint was absolute change in QLQ-INFO25 questionnaire (paired t-test, adjusted α=0.0166) between baseline and M6 in perception of information about disease, treatment, and supportive care. Secondary endpoints were other dimensions of QLQ-INFO25 and QLQ-C30. Full analysis set (FAS) was all treated patients with ≥1 of the 3 dimensions of the primary endpoint available at baseline and M6.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Walter T, Do Cao C, Coriat R, Dominguez S,

Keywords: somatostatin analogues, quality of life, QLQINFO25, QLQC30, gastroenteropancreatic neuroendocrine tumor,